


**Supplementary information**


# Prevention of tuberculosis in macaques after intravenous BCG immunization

In the format provided by the authors and unedited


Patricia A. Darrah, Joseph J. Zeppa, Pauline Maiello, Joshua A. Hackney, Marc H. Wadsworth II, Travis K. Hughes, Supriya Pokkali, Phillip A. Swanson II, Nicole L. Grant, Mark A. Rodgers, Megha Kamath, Chelsea M. Causgrove, Dominick J. Laddy, Aurelio Bonavia, Danilo Casimiro, Philana Ling Lin, Edwin Klein, Alexander G. White, Charles A. Scanga, Alex K. Shalek, Mario Roederer, JoAnne L. Flynn & Robert A. Seder



**Supplementary Data 1: Dose-finding pilot study in NHP.** To determine a BCG dose and vaccination route that would elicit greater immune responses in the BAL compared to the standard human BCG vaccine regimen ( $5 \times 10^5$  CFU ID), 3 NHP per group (24 total macaques, 22 male and 2 female; 6–9 years old) were immunized with BCG by different routes and nominal doses as follows: ID only ( $1 \times 10^5$  CFU); AE ( $1 \times 10^3$ ,  $1 \times 10^5$ , or  $1 \times 10^7$  CFU) plus ID ( $1 \times 10^5$  CFU); AE only ( $5 \times 10^5$  or  $5 \times 10^7$  CFU); IV only ( $5 \times 10^5$  or  $5 \times 10^7$  CFU). Actual BCG doses can be found in **Extended Data Fig. 1c** (Pilot cohorts a–c). Prior to (Pre, P) and at various weeks after BCG immunization, BAL was collected from each macaque to perform *in vitro* T cell stimulation and flow cytometric cytokine analysis. Shown are the frequencies (log scale) of memory CD4 T cells producing any combination of IFN $\gamma$ , IL-2, or TNF (top), memory CD4 T cells producing IL-17 (with or without other cytokines; middle), and memory CD8 T cells producing IFN $\gamma$ , IL-2, or TNF (bottom) in response to PPD stimulation for 3 individual macaques through 24 weeks after BCG. No statistical comparisons were performed in this pilot study. For challenge studies, a dose of  $\sim 5 \times 10^7$  CFU BCG was selected based on the capacity of this dose to elicit robust cellular immunity when administered AE and IV.




**Supplementary Data 2: Cell counts in the BAL after BCG vaccination.** **a**, Total number of viable, nucleated cells isolated from the BAL collected from BCG-immunized NHP (cohorts 1–4,  $n = 11$ –13 macaques) before vaccination (P) and after BCG, as determined by ethidium bromide/acridine dual-fluorescence automated counting. Circles represent individual macaques from challenge cohorts (1–3,  $n = 8$ –11) that were not lavaged within 8 week before challenge (per protocol); triangles are macaques from cohort 4 ( $n = 3$ ) that were used for immunological measurements only and sampled through week 24 after BCG. Line represents the median for each group over time. **b**, Number of cells of indicated leukocyte population in the BAL of immunized NHP 8 weeks after BCG, as determined by flow cytometry (identified as in **Supplementary Data 8**). For each subset, the frequency of live cells was multiplied by the number of viable nucleated cells harvested from the BAL. Data points are individual macaques ( $n = 11$ –13 macaques except  $\gamma\delta$ , and iNKT cells,  $n = 3$  macaques) and horizontal lines represent the geometric means that were used to generate **Fig. 1a**. T, T cells; B, B cells; mDC, myeloid dendritic cells; pDC, plasmacytoid dendritic cells; Neut, neutrophils; NK, NK cells; CD4, CD4 T cells; CD8, CD8 T cells; V $\gamma$ 9<sup>+</sup>, V $\gamma$ 9<sup>+</sup>  $\gamma\delta$  T cells; MAIT, mucosal associated invariant T cells; iNKT, invariant natural killer T cells. Kruskal-Wallis tests were run and reported  $P$  values represent Dunn's multiple comparison test comparing each vaccine group to ID<sub>low</sub>.




**Supplementary Data 3: Innate cytokine production from PBMCs after BCG vaccination.** Studies show that recent Mtb exposure or BCG immunization in humans leads to increased innate cytokine production following stimulation of PBMCs with unrelated microbial stimuli. This “trained innate immunity” has been associated with growth inhibition of BCG by PBMCs *in vitro*, and enhanced protection in mice after IV BCG vaccination. **a**, To investigate if a trained immune effect could be detected, PBMCs from NHP ( $n = 8$  macaques) before BCG (pre-vax) and at 4 and 24 weeks after ID<sub>low</sub>- or IV-BCG immunization were stimulated *in vitro* with medium alone, Mtb whole cell lysate (Mtb), heat-killed *Staphylococcus aureus* (HkSA), or LPS for 24 hours. TNF, IL-1 $\beta$  and IL-6 were measured as primary indicators of trained immunity; however, no increases in cytokines were observed for either vaccine group after vaccination. **b**, As a positive control for antigen-specific T cell stimulation, we measured IFN $\gamma$ . Consistent with the flow cytometry data in **Fig. 1b, c**, PBMCs from IV BCG-immunized NHP secreted higher levels of IFN $\gamma$  compared to ID<sub>low</sub>-immunized NHP in response to Mtb at 4 and 24 weeks after BCG (2-way ANOVA;  $P$  values are Dunnett’s multiple comparisons test).

## Supplementary Data 4




**Supplementary Data 4: Quality of T cell responses in PBMCs after BCG immunization.** **a**, The frequency of PPD-responsive CD4 memory T cells in PBMCs expressing CD154 with any combination of IFN $\gamma$ , IL-2, or TNF, or the frequency of total IL-17 production, for macaques in each vaccine group (challenge cohorts 1–3, n = 8–11 macaques) at 4, 8, 16 and 24 weeks after BCG immunization. **b**, Pie graphs represent the proportions of total cytokine production comprising each cytokine combination as shown in (a), averaged for macaques in each group at each time point. Individual macaque responses are shown with interquartile range (bar) and median (horizontal line). Note that the proportion of the response producing IL-17 (with or without other cytokines) is indicated with a black arc and CD4 T cells that express CD154 (without other cytokines) are the black pie section. **c**, The frequency of PPD-responsive CD8 memory T cells in PBMCs expressing any combination of IFN $\gamma$ , IL-2, or TNF in PBMCs after BCG immunization. **d**, Proportion of total cytokine response comprising each individual cytokine combination for vaccine groups that measurable CD8 T cell responses.

## Supplementary Data 5




**Supplementary Data 5: Quality of T cell responses in BAL after BCG immunization.** **a**, The frequency of PPD-responsive CD4 memory T cells in BAL expressing any combination of IFN $\gamma$ , IL-2, or TNF, or the frequency of total IL-17 production, for NHP in each vaccine group (challenge cohorts 1–3, n = 8–11 macaques) at 4, 8, 12 and 16 weeks after BCG immunization (per protocol, BAL was not sampled within 8 weeks of Mtb challenge). Individual macaque responses are shown with interquartile range (bar) and median (horizontal line). **b**, The proportion of total cytokine production comprising each cytokine combination as shown in **(a)** averaged for macaques in each group at each time point. Note that the proportion of the response producing IL-17 (with or without other cytokines) is indicated with a black arc and IL-17-single positive cells are represented by the grey pie section. CD154 expression was not measured in the BAL. **c, d**, The frequency and proportion CD8 T cell responses following PPD stimulation as described above.


## Supplementary Data 6



**Supplementary Data 6: Data quality metrics for single-cell mRNA sequencing (Seq-Well).** **a**, Scatterplots showing the relationship between the ratios of macrophages (Mac) to T cells (T) in BAL measured by flow cytometry and Seq-Well at week 13 (top) and week 25 (bottom) after BCG immunization. Data points are individual macaques (cohort 4,  $n = 3$  macaques), color-coded by vaccine. At both time points, a significant correlation was observed between the ratio of macrophages to T cells in BAL between flow cytometric analysis (**Extended Data Fig. 3a**) and single-cell RNA-sequencing (Week 13:  $R = 0.75$ ,  $P = 1.3 \times 10^{-3}$ ; Week 24:  $R = 0.881$ ,  $P = 1.4 \times 10^{-5}$ ) **b**, Stacked bar graphs showing the cellular composition of BAL (percent of each indicated cell type in all cells combined) for each macaque in each vaccine group at weeks 13 (top) and 25 (bottom) after BCG immunization. Macrophages and T cells are depicted in green and pink, respectively. **c**, For the Seq-Well analysis, number of genes, unique molecular identifiers (UMI), and reads per cell (unstimulated and stimulated cells combined) for each macaque at weeks 13 (top) and 25 (bottom) after quality filtering (**Methods**).




**Supplementary Data 7: Detection of CD8 T cells in lung tissue following IV BCG.** **a**, 1 month after BCG vaccination, tissue- versus blood-derived T cells in lung were delineated by injecting NHP IV with a fluorochrome-conjugated anti-CD45 antibody (ivCD45) prior to euthanasia, labelling leukocytes in the vasculature. Macaques (cohort 6, n = 2) received  $5 \times 10^7$  CFU BCG ID, IV, AE, or endobronchially (EB) into the left lung. Cells isolated from BAL and each lung lobe were stained immediately ex vivo for surface marker expression (**a**) or stimulated with Mtb WCL and stained for intracellular cytokine expression (**b**, **c**), and then analyzed by flow cytometry. Shown are plots of CD8 T cells derived from the BAL and lung lobes (R, right; L, left; U, upper; M, middle; L, lower) from 1 of 2 macaques per group as shown in **Fig. 4a**. **a**, The percent of ivCD45<sup>-</sup> (unstimulated) CD8 T cells expressing the tissue-residency/activation marker CD69 for each macaque. **b**, Shown is the percent of Mtb WCL-responsive (IFN $\gamma$ <sup>+</sup>) CD8 T cells in the BAL and lung tissue (ivCD45<sup>-</sup>) following IV BCG. **c**, IFN $\gamma$  production (black) as identified in (**b**) is overlaid on total CD8 memory T cells (grey); percentages indicate the proportion of IFN $\gamma$ <sup>+</sup> CD8 T cells expressing CD69 and CD103.




**Supplementary Data 8: Antibody panel and gating strategy used to analyze cellular composition of BAL and PBMCs after BCG vaccination.** The gating strategy shown was used to determine the frequencies of leukocyte populations in the BAL and PBMCs before and after BCG vaccination, as in **Fig. 1a**, **Supplementary Data 2b**, and **Extended Data Fig. 3**. Unstimulated cells were stained for viability and then surface-stained with remaining antibodies listed. A generous “live” gate was applied to include auto-fluorescent alveolar macrophages. CD45<sup>+</sup> leukocytes were gated first, followed by CD163<sup>+</sup>CD11c<sup>+</sup> alveolar macrophages. From non-macrophages, CD20<sup>+</sup> B cells, CD3<sup>+</sup> T cells, and non-B, non-T cells were gated. T cells were further delineated as V $\gamma$ 9<sup>+</sup>  $\gamma$ δ<sup>+</sup> or V $\gamma$ 9<sup>-</sup>  $\gamma$ δ<sup>+</sup> T cells, CD161<sup>+</sup>MR1<sup>+</sup> MAIT cells, CD161<sup>+</sup>6b11<sup>+</sup> iNKT cells (observed rarely in NHP BAL), and CD4<sup>+</sup> or CD8<sup>+</sup> T cells. Neutrophils (CD66abce<sup>+</sup>CD11b<sup>+</sup>) and NK cells (NKG2A<sup>+</sup>) were gated from non-B, non-T cells. HLA-DR<sup>+</sup> cells were then gated as either CD11c<sup>+</sup> myeloid dendritic cells (mDC) or plasmacytoid dendritic cells (pDC). In some samples, CD66abce alone was used to define neutrophils and we cannot rule out eosinophil contamination. # indicates different markers conjugated to the same fluorochrome but used at different time points.

## Supplementary Data 9





**Supplementary Data 9: Antibody panel and gating strategy used to measure antigen-responsive CD4 and CD8 T cells in BAL after BCG immunization.** The flow cytometric gating strategy shown was applied to BAL (or tissue) samples following in vitro stimulation with antigen and intracellular cytokine staining, as in (Fig. 1d, e, Extended Data Fig. 4c, d, and Supplementary Data 5). **a**, A narrow singlet gate excludes many alveolar macrophages; live CD3+ T cells were gated using FSC-A by SSC-A, followed by exclusion of dead cells. CD4+ or CD8+ T cells were identified, followed by gating for memory T cells. We use CD28 and CD45RA to identify total memory in BAL although few naïve (CD28+CD45RA+) T cells are present. Memory populations in the BAL were classified as transitional memory ( $T_{TM}$ ; CD28+CD45RA-), effector memory ( $T_{EM}$ ; CD28-CD45RA-), or terminal effectors ( $T_{EF}$ ; CD28-CD45RA+). As BAL T cells are largely negative for CCR7 staining (**b**) compared to CCR7 staining of lymph node from the same macaque), we did not apply a gate to distinguish central memory T cells ( $T_{CM}$ ; CD28+CD45RA-CCR7+) from  $T_{TM}$  (CD28+CD45RA-CCR7-). **c**, From total CD4 or CD8 memory, IFN $\gamma$ , IL-2, TNF or IL-17 production was gated against the activation marker, CD69. Shown is a representative BAL sample from an IV BCG-immunized NHP, after no stimulation or PPD stimulation; it is common to see ‘background’ cytokine production from unstimulated NHP BAL. **d**, Typical expression of CD103 on BAL CD4 and CD8 T cells, shown against cytokines from a PPD-stimulated sample. **e**, CD154 was included in the intracellular staining mix of some, but not all, BAL samples; CD154 was largely co-expressed with IFN $\gamma$  and TNF. **f**, Antibodies used in panel; markers in parenthesis were included at some, but not all time points. In a limited number of samples, antigen-induced IL-10 or IL-4 production was tested but not detected in the BAL. For ivCD45-injected macaques, IFN $\gamma$  clone B27 conjugated to BB700 (BD Bioscience) was used.

## Supplementary Data 10




**Supplementary Data 10: Antibody panel and gating strategy used to measure antigen-responsive CD4 and CD8 T cells in PBMCs after BCG immunization.** The flow cytometric gating strategy was applied to batch-analyzed PBMCs following antigen-stimulation and intracellular cytokine staining to assess the frequency and quality of cytokine producing T cells and the memory phenotype of the response, as in **Fig. 1b**, **c**, **Extended Data Fig. 4a, b, e, f, and Supplementary Data 4**. **a**, Total PBMCs were gated for singlets, followed by a lymphocyte gate (SSC-A by FSC-A), a dump gate to remove HLA-DR high cells, and a viability gate to exclude dead cells. CD3<sup>+</sup> T cells gated as V $\gamma$ 9<sup>+</sup>  $\gamma$ δ<sup>+</sup> T cells or  $\gamma$ δ<sup>-</sup> CD4<sup>+</sup> and CD8<sup>+</sup> T cells. For each T cell subset, naïve (CD28<sup>+</sup>CD45RA<sup>+</sup>) cells were excluded and effector molecules were gated on total memory cells. **b**, Shown is a representative PBMCs sample from an IV BCG-immunized macaque with or without PPD stimulation. IFN $\gamma$ , IL-2, TNF, IL-17 and CD154 were gated against the activation marker, CD69. **c**, The memory phenotype of the antigen-responsive T cell response was determined by gating on total CD4 or CD8 T cells and applying those gates to the Boolean-gated population of T cells producing any combination of cytokines measured. Pie charts display the proportion of the response that are central memory (T<sub>CM</sub>; CD28<sup>+</sup>CD45RA<sup>-</sup>CCR7<sup>+</sup>), transitional memory (T<sub>TM</sub>; CD28<sup>+</sup>CD45RA<sup>-</sup>CCR7<sup>-</sup>), effector memory (T<sub>EM</sub>; CD28<sup>-</sup>CD45RA<sup>-</sup>), or terminal effectors (T<sub>EF</sub>; CD28<sup>-</sup>CD45RA<sup>+</sup>). **d**, Antibodies used in panel.

**a****b****c**

Ki-67 Panel			
Marker	Color	Clone	Company
CCR7	BV510	G043H7	BioLegend
CD153	PE	116614	R&D
CD154	BV421	TRAP1	BD Biosciences
CD28	PE/Cy5	CD28.2	BD Biosciences
CD3	APC/Cy7	SP34-2	BD Biosciences
CD4	BUV496	SK3	BD Biosciences
CD45RA	BV711	5H9	BD Biosciences
CD8	BUV805	RPA-T8	BD Biosciences
IFNg	APC	B27	BD Biosciences
IL-17a	BV570	BL168	BioLegend
IL-2	BV750	MQ1-17H12	BD Biosciences
Ki67	FITC	Ki67	BD Biosciences
Tbet	PE/Cy7	4B10	BioLegend
TNF	BV650	Mab11	BD Biosciences

**Supplementary Data 11: Antibody panel and gating strategy to identify Ki-67-positive antigen-responsive CD4 and CD8 T cells in PBMCs after BCG immunization.** The flow cytometric gating strategy was applied to PBMCs to identify the proportion of antigen-responsive CD4 and CD8 T cells that express the marker of proliferation, Ki-67, as in **Extended Data Fig. 4g–j**. As described in the methods, a multi-step staining protocol was used to optimize cytoplasmic cytokine and nuclear Ki-67 detection after in vitro antigen stimulation. Shown is a representative PBMC sample from an IV BCG-immunized NHP. **a**, Gating for cytokine-positive memory CD4 and CD8 T cells is shown in **Supplementary Data 10**. **b**, Ki-67 was gated on total CD4 or CD8 memory cells (all non-naïve) compared to naïve T cells and then the Ki-67<sup>+</sup> gate was applied to all antigen-responsive T cells. **c**, Antibodies used in panel.



**Supplementary Data 12. Disease severity in unvaccinated rhesus macaques across Mtb challenge doses.** Total Mtb CFU ( $\log_{10}$ ) following Mtb challenge of unvaccinated rhesus macaques in this study (black dots,  $n = 4$ ) is similar to that reported in our previous study (grey dots,  $n = 12$ ), with infection doses ranging from 8–16 CFU.